T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
Raises $110m In Series B
Executive Summary
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
You may also be interested in...
Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
How Nordic Nanovector Stepped Back From The Abyss With APIM Merger
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
Poland’s Ryvu Bets Big On Blood Cancer Candidate
Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.